T10	Exp 353 364	its binding
T11	Exp 237 241	that
T12	Exp 312 342	the HIV-1 long terminal repeat
T13	Exp 368 404	the transactivation response element
T14	Exp 532 550	the HIV-1 promoter
T15	Exp 762 799	this Tat-mediated LTR superactivation
T16	Exp 804 814	this study
T17	Exp 1281 1297	the combined use
T18	Exp 1330 1359	the two NF-kappa B inhibitors
T19	Exp 1369 1378	the virus
T20	Exp 1382 1398	the latent state
T21	Exp 1423 1445	The combined treatment
T22	Exp 1522 1547	the NF-kappa B inhibitors
T23	Exp 1557 1585	the anti-Tat sFv intrabodies
T24	Exp 1625 1629	that
T25	Exp 1721 1728	the one
T26	Exp 1755 1767	the survival
T27	Exp 1603 1616	these results
R3	Coref Anaphora:T11 Antecedent:T28
R4	Coref Anaphora:T10 Antecedent:T2
T1	Protein 102 105	Tat
T2	Protein 204 207	Tat
T3	Protein 508 511	Tat
T4	Protein 598 625	tumor necrosis factor alpha
T5	Protein 715 718	Tat
T6	Protein 767 770	Tat
T7	Protein 963 966	Tat
T8	Protein 1306 1309	Tat
T9	Protein 1566 1569	Tat
T28	Exp 209 236	an early regulatory protein
